New targeted therapies such as anti-adhesion molecules, anti-IL-12/23 and anti-Janus kinases are looking toward a more effective treatment of inflammatory bowel disease

References

• NAMolodecky, ISSoon, DMRabi, WAGhali, MFerris, GChernoff, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012;142:46–54. e42; quiz e30.
   PubMed Web of Science ®Google Scholar
• SJPark, WHKim, JHCheon. Clinical characteristics and treatment of inflammatory bowel disease: a comparison of Eastern and Western perspectives. World J Gastroenterol 2014;20:11525–37.
   PubMed Web of Science ®Google Scholar
• JFColombel, WJSandborn, PRutgeerts, REnns, SBHanauer, RPanaccione, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 2007;132:52–65.
   PubMed Web of Science ®Google Scholar
• SBHanauer, BGFeagan, GRLichtenstein, LFMayer, SSchreiber, JFColombel, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002;359:1541–9.
   PubMed Web of Science ®Google Scholar
• SBHanauer, WJSandborn, PRutgeerts, RNFedorak, MLukas, DMacIntosh, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 2006;130:323–33. quiz 591.
   PubMed Web of Science ®Google Scholar
• WReinisch, WJSandborn, DWHommes, GD’Haens, SHanauer, SSchreiber, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011;60:780–7.
   PubMed Web of Science ®Google Scholar
• PRutgeerts, WJSandborn, BGFeagan, WReinisch, AOlson, JJohanns, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462–76.
   PubMed Web of Science ®Google Scholar
• WJSandborn, BGFeagan, CMarano, HZhang, RStrauss, JJohanns, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014;146:85–95. quiz e14-5.
   PubMed Web of Science ®Google Scholar
• WJSandborn, BGFeagan, SStoinov, PJHoniball, PRutgeerts, DMason, et al. Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med 2007;357:228–38.
   PubMed Web of Science ®Google Scholar
• WJSandborn, SBHanauer, PRutgeerts, RNFedorak, MLukas, DGMacIntosh, et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut 2007;56:1232–9.
   PubMed Web of Science ®Google Scholar
• WJSandborn, Gvan Assche, WReinisch, JFColombel, GD’Haens, DCWolf, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012;142:257–65. e1-3.
   PubMed Web of Science ®Google Scholar
• BESands, FHAnderson, CNBernstein, WYChey, BGFeagan, RNFedorak, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 2004;350:876–85.
   PubMed Web of Science ®Google Scholar
• SSchreiber, MKhaliq-Kareemi, ICLawrance, OOThomsen, SBHanauer, JMcColm, et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med 2007;357:239–50.
   PubMed Web of Science ®Google Scholar
• KTThia, WJSandborn, WSHarmsen, ARZinsmeister, EVLoftusJr. Risk factors associated with progression to intestinal complications of Crohn’s disease in a population-based cohort. Gastroenterology 2010;139:1147–55.
   PubMed Web of Science ®Google Scholar
• ICSolberg, ILygren, JJahnsen, EAadland, OHoie, MCvancarova, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol 2009;44:431–40.
   PubMed Web of Science ®Google Scholar
• GFiorino, LPeyrin-Biroulet, SDanese. Bowel damage assessment in Crohn’s disease by magnetic resonance imaging. Curr Drug Targets 2012;13:1300–7.
   PubMedGoogle Scholar
• JBurisch, TJess, MMartinato, PLLakatos. The burden of inflammatory bowel disease in Europe. J Crohns Colitis 2013;7:322–37.
   PubMed Web of Science ®Google Scholar
• ACFord, WJSandborn, KJKhan, SBHanauer, NJTalley, PMoayyedi. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011;106:644–59. quiz 660.
   PubMed Web of Science ®Google Scholar
• LPeyrin-Biroulet, PDeltenre, Nde Suray, JBranche, WJSandborn, JFColombel. Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008;6:644–53.
   PubMed Web of Science ®Google Scholar
• SDanese, JFColombel, LPeyrin-Biroulet, PRutgeerts, WReinisch. Review article: the role of anti-TNF in the management of ulcerative colitis – past, present and future. Aliment Pharmacol Ther 2013;37:855–66.
   PubMed Web of Science ®Google Scholar
• SDanese, GFiorino, LPeyrin-Biroulet, ELucenteforte, GVirgili, LMoja, et al. Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Ann Intern Med 2014;160:704–11.
   PubMed Web of Science ®Google Scholar
• AOussalah, SDanese, LPeyrin-Biroulet. Efficacy of TNF antagonists beyond one year in adult and pediatric inflammatory bowel diseases: a systematic review. Curr Drug Targets 2010;11:156–75.
   PubMedGoogle Scholar
• LPeyrin-Biroulet. Anti-TNF therapy in inflammatory bowel diseases: a huge review. Minerva Gastroenterol Dietol 2010;56:233–43.
   PubMedGoogle Scholar
• DGBinion, GAWest, KIna, NPZiats, SNEmancipator, CFiocchi. Enhanced leukocyte binding by intestinal microvascular endothelial cells in inflammatory bowel disease. Gastroenterology 1997;112:1895–907.
   PubMed Web of Science ®Google Scholar
• GGorfu, JRivera-Nieves, KLey. Role of beta7 integrins in intestinal lymphocyte homing and retention. Curr Mol Med 2009;9:836–50.
   PubMed Web of Science ®Google Scholar
• JPanes, DCAnderson, MMiyasaka, DNGranger. Role of leukocyte-endothelial cell adhesion in radiation-induced microvascular dysfunction in rats. Gastroenterology 1995;108:1761–9.
   PubMed Web of Science ®Google Scholar
• MSans, JPanes, EArdite, JIElizalde, YArce, MElena, et al. VCAM-1 and ICAM-1 mediate leukocyte-endothelial cell adhesion in rat experimental colitis. Gastroenterology 1999;116:874–83.
   PubMed Web of Science ®Google Scholar
• SThomas, DCBaumgart. Targeting leukocyte migration and adhesion in Crohn’s disease and ulcerative colitis. Inflammopharmacology 2012;20:1–18.
   PubMedGoogle Scholar
• WJSandborn, JFColombel, REnns, BGFeagan, SBHanauer, ICLawrance, et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med 2005;353:1912–25.
   PubMed Web of Science ®Google Scholar
• SRTargan, BGFeagan, RNFedorak, BALashner, RPanaccione, DHPresent, et al. Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE Trial. Gastroenterology 2007;132:1672–83.
   PubMed Web of Science ®Google Scholar
• EOMajor. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 2010;61:35–47.
   PubMed Web of Science ®Google Scholar
• BGFeagan, PRutgeerts, BESands, SHanauer, JFColombel, WJSandborn, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699–710.
   PubMed Web of Science ®Google Scholar
• WJSandborn, BGFeagan, PRutgeerts, SHanauer, JFColombel, BESands, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 2013;369:711–21.
   PubMed Web of Science ®Google Scholar
• BESands, BGFeagan, PRutgeerts, JFColombel, WJSandborn, RSy, et al. Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology 2014;147:618–27. e3.
   PubMed Web of Science ®Google Scholar
• JFColombel, BSands, SHanauer, PRutgeerts, WSandborn, SDanese, et al. Long-term safety of vedolizumab for the treatment of ulcerative colitis or crohn’s disease. 78th Annual Scientific Meeting of the American College of Gastroenterology; San Diego, CA, USA; 2013. Journal 2013.
   Google Scholar
• SJBickston, BWBehm, DJTsoulis, JCheng, JKMacDonald, RKhanna, et al. Vedolizumab for induction and maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2014;8:CD007571.
   PubMedGoogle Scholar
• BGFeagan, JWMcDonald, GRGreenberg, GWild, PPare, RNFeagan, et al. An ascending dose trial of a humanized A4B7 antibody in ulcerative colitis. Gastroenterology 2000;118:A874.
   Web of Science ®Google Scholar
• BGFeagan, GRGreenberg, GWild, RNFedorak, PPare, JWMcDonald, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005;352:2499–507.
   PubMed Web of Science ®Google Scholar
• AParikh, TLeach, TWyant, CScholz, SSankoh, DRMould, et al. Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis 2012;18:1470–9.
   PubMed Web of Science ®Google Scholar
• Available from http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002782/smops/Positive/human_smop_000663.jsp&mid=WC0b01ac058001d127. Accessed on 15 October 2014.
   Google Scholar
• WJPan, KKock, WARees, BASullivan, CMEvangelista, MYen, et al. Clinical pharmacology of AMG 181, a gut-specific human anti-alpha beta monoclonal antibody, for treating inflammatory bowel diseases. Br J Clin Pharmacol 2014;78:1315–33.
   PubMed Web of Science ®Google Scholar
• AMG 181 phase 2 study in subjects with moderate to severe ulcerative colitis. Available from http://clinicaltrials.gov/show/NCT01694485. Accessed on 13 November 2014.
   Google Scholar
• AMG 181 in subjects with moderate to severe crohn’s disease. Available from http://clinicaltrials.gov/show/NCT01696396. Accessed on 13 November 2014.
   Google Scholar
• EGStefanich, DMDanilenko, HWang, SO’Byrne, RErickson, TGelzleichter, et al. A humanized monoclonal antibody targeting the beta7 integrin selectively blocks intestinal homing of T lymphocytes. Br J Pharmacol 2011;162:1855–70.
   PubMed Web of Science ®Google Scholar
• PJRutgeerts, RNFedorak, DWHommes, ASturm, DCBaumgart, BBressler, et al. A randomised phase I study of etrolizumab (rhuMAb beta7) in moderate to severe ulcerative colitis. Gut 2013;62:1122–30.
   PubMed Web of Science ®Google Scholar
• SVermeire, SO’Byrne, MKeir, MWilliams, TTLu, JCMansfield, et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet 2014;384:309–18.
   PubMed Web of Science ®Google Scholar
• A study of the efficacy and safety of etrolizumab treatment, compared with adalimumab and placebo, in inducing disease remission in ulcerative colitis patients who have not previously received TNF inhibitors (Study #2). Available from http://clinicaltrials.gov/show/NCT02171429. Accessed on 15 October 2014.
   Google Scholar
• AAndou, THisamatsu, SOkamoto, HChinen, NKamada, TKobayashi, et al. Dietary histidine ameliorates murine colitis by inhibition of proinflammatory cytokine production from macrophages. Gastroenterology 2009;136:564–74. e2.
   PubMed Web of Science ®Google Scholar
• YIkenoue, TTagami, MMurata. Development and validation of a novel IL-10 deficient cell transfer model for colitis. Int Immunopharmacol 2005;5:993–1006.
   PubMedGoogle Scholar
• TSugiura, SKageyama, AAndou, TMiyazawa, CEjima, ANakayama, et al. Oral treatment with a novel small molecule alpha 4 integrin antagonist, AJM300, prevents the development of experimental colitis in mice. J Crohns Colitis 2013;7:e533–42.
   PubMedGoogle Scholar
• MTakazoe, MWatanabe, TKawaguchi, TMatsumoto, NOshitani, NHiwatashi, et al. S1066 Oral Alpha-4 integrin inhibitor (AJM300) in patients with active Crohn’s disease – a randomized, double-blind, placebo-controlled trial. Gastroenterology 2009;136:A-181.
   Google Scholar
• MWatanabe, NYoshimura, SMotoya, KTominaga, RIwakiri, KWatanabe, et al. AJM300, an oral alpha4 integrin antagonist for active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled phase 2A study. Gastroenterology 2014;146:S82.
   Google Scholar
• GD’Haens, SVermeire, FCataldi, HVogelsang, MAllez, PDesreumaux, et al. Anti-MAdCAM monoclonal antibody PF-00547659 does not affect immune surveillance in the central nervous system of anti-TNF and immunosuppressant experienced Crohn’s disease patients who are anti-TNF inadequate responders. Results from the TOSCA study 9th Congress of ECCO (ECCO2014); Copenhagen Denmark; 2014. Journal 2014 p OP007.
   Google Scholar
• SBrand. Crohn’s disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn’s disease. Gut 2009;58:1152–67.
   PubMed Web of Science ®Google Scholar
• GMonteleone, LBiancone, RMarasco, GMorrone, OMarasco, FLuzza, et al. Interleukin 12 is expressed and actively released by Crohn’s disease intestinal lamina propria mononuclear cells. Gastroenterology 1997;112:1169–78.
   PubMed Web of Science ®Google Scholar
• PParronchi, PRomagnani, FAnnunziato, SSampognaro, ABecchio, LGiannarini, et al. Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn’s disease. Am J Pathol 1997;150:823–32.
   PubMed Web of Science ®Google Scholar
• TParrello, GMonteleone, SCucchiara, IMonteleone, LSebkova, PDoldo, et al. Up-regulation of the IL-12 receptor beta 2 chain in Crohn’s disease. J Immunol 2000;165:7234–9.
   PubMed Web of Science ®Google Scholar
• YIwakura, HIshigame. The IL-23/IL-17 axis in inflammation. J Clin Invest 2006;116:1218–22.
   PubMed Web of Science ®Google Scholar
• CLLangrish, YChen, WMBlumenschein, JMattson, BBasham, JDSedgwick, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005;201:233–40.
   PubMed Web of Science ®Google Scholar
• LEHarrington, RDHatton, PRMangan, HTurner, TLMurphy, KMMurphy, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005;6:1123–32.
   PubMed Web of Science ®Google Scholar
• RHDuerr, KDTaylor, SRBrant, JDRioux, MSSilverberg, MJDaly, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006;314:1461–3.
   PubMed Web of Science ®Google Scholar
• RAKastelein, CAHunter, DJCua. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu Rev Immunol 2007;25:221–42.
   PubMed Web of Science ®Google Scholar
• KWang, HZhang, SKugathasan, VAnnese, JPBradfield, RKRussell, et al. Diverse genome-wide association studies associate the IL12/IL23 pathway with Crohn Disease. Am J Hum Genet 2009;84:399–405.
   PubMed Web of Science ®Google Scholar
• WStrober, FZhang, AKitani, IFuss, SFichtner-Feigl. Proinflammatory cytokines underlying the inflammation of Crohn’s disease. Curr Opin Gastroenterol 2010;26:310–17.
   PubMed Web of Science ®Google Scholar
• CTillack, LMEhmann, MFriedrich, RPLaubender, PPapay, HVogelsang, et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-gamma-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut 2014;63:567–77.
   PubMed Web of Science ®Google Scholar
• PJMannon, IJFuss, LMayer, COElson, WJSandborn, DPresent, et al. Anti-interleukin-12 antibody for active Crohn’s disease. N Engl J Med 2004;351:2069–79.
   PubMed Web of Science ®Google Scholar
• WJSandborn, CGasink, LLGao, MBlank, JJohanns, CGuzzo, et al. A multicenter, randomized, double-blind, placebo-controlled study phase2b of ustekinumab, a human monoclonal antibody to IL-12/ 23p40, in patients with moderately to severely active Crohn’s disease: results through week 22 from the Certifi trial. Gastroenterology 2011;140:S-109.
   Google Scholar
• WJSandborn, BGFeagan, RNFedorak, EScherl, MRFleisher, SKatz, et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease. Gastroenterology 2008;135:1130–41.
   PubMed Web of Science ®Google Scholar
• WJSandborn, CGasink, LLGao, MABlank, JJohanns, CGuzzo, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med 2012;367:1519–28.
   PubMed Web of Science ®Google Scholar
• UKopylov, WAfif, ACohen, ABitton, GWild, TBessissow, et al. Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn’s disease-the McGill experience. J Crohns Colitis 2014;8(11):1516–22.
   PubMed Web of Science ®Google Scholar
• A study to evaluate the safety and efficacy of ustekinumab in patients with moderately to severely active Crohn’s disease who have failed or are intolerant to tumor necrosis factor (TNF) antagonist therapy (UNITI-1). Available from http://clinicaltrials.gov/show/NCT01369329. Accessed on 15 October 2014.
   Google Scholar
• A study to evaluate the safety and efficacy of ustekinumab in patients with moderately to severely active Crohn’s disease (UNITI-2). Available from http://clinicaltrials.gov/show/NCT01369342. Accessed on 15 October 2014.
   Google Scholar
• A study to evaluate the safety and efficacy of ustekinumab maintenance therapy in patients with moderately to severely active Crohn’s disease (IM-UNITI). Available from http://clinicaltrials.gov/show/NCT01369355. Accessed on 15 October 2014.
   Google Scholar
• JEDarnellJr. STATs and gene regulation. Science 1997;277:1630–5.
   PubMed Web of Science ®Google Scholar
• KGhoreschi, ALaurence, JJO’Shea. Janus kinases in immune cell signaling. Immunol Rev 2009;228:273–87.
   PubMed Web of Science ®Google Scholar
• AGHarpur, ACAndres, AZiemiecki, RRAston, AFWilks. JAK2, a third member of the JAK family of protein tyrosine kinases. Oncogene 1992;7:1347–53.
   PubMed Web of Science ®Google Scholar
• TKisseleva, SBhattacharya, JBraunstein, CWSchindler. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene 2002;285:1–24.
   PubMed Web of Science ®Google Scholar
• PSaharinen, OSilvennoinen. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J Biol Chem 2002;277:47954–63.
   PubMed Web of Science ®Google Scholar
• SDanese, CFiocchi. Ulcerative colitis. N Engl J Med 2011;365:1713–25.
   PubMed Web of Science ®Google Scholar
• WJSandborn, SGhosh, JPanes, IVranic, CSu, SRousell, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012;367:616–24.
   PubMed Web of Science ®Google Scholar
• WJSandborn, SGhosh, JPanes, IVranic, WWang, WNiezychowski. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn’s disease. Clin Gastroenterol Hepatol 2014;12:1485–93. e2.
   PubMed Web of Science ®Google Scholar